Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -253.57% is 144% below its 5-year average of -104.05%, near the low end of its 5-year range (-343.93%–-31.47%).
As of the fiscal period ended Tuesday, June 30, 2026. 11.37% below its 12-month average of -227.69%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -253.57%.
RETURN ON EQUITY (ROE)
-253.57%
RETURN ON EQUITY (ROE) AVG TTM
-227.69%
RETURN ON EQUITY (ROE) AVG 3Y
-154.33%
RETURN ON EQUITY (ROE) AVG 5Y
-104.05%
RETURN ON EQUITY (ROE) AVG 10Y
-94.25%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-11.37%
CURRENT VS 3Y AVG
-64.30%
CURRENT VS 5Y AVG
-143.70%
CURRENT VS 10Y AVG
-169.05%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-37.66%
median of 436 covered companies
CURRENT VS SECTOR MEDIAN
-573.32%
vs the sector median at left
Artelo Biosciences, Inc.
Market Cap
$1.36M
Return on Equity (ROE)
-253.57%
TTM Avg
-227.69%
3Y Avg
-154.33%
5Y Avg
-104.05%
Market Cap
$1.37M
Return on Equity (ROE)
-111.51%
TTM Avg
-753.43%
3Y Avg
-507.39%
5Y Avg
-356.28%
Market Cap
$1.48M
Return on Equity (ROE)
-32.05%
TTM Avg
-197.10%
3Y Avg
-44.98%
5Y Avg
-69.38%
Market Cap
$1.49M
Return on Equity (ROE)
-80.57%
TTM Avg
-96.07%
3Y Avg
-115.92%
5Y Avg
51.19%
Market Cap
$1.50M
Return on Equity (ROE)
-169.64%
TTM Avg
97.92%
3Y Avg
65.28%
5Y Avg
65.28%
Market Cap
$1.54M
Return on Equity (ROE)
-450.54%
TTM Avg
292.29%
3Y Avg
55.45%
5Y Avg
24.80%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
206.72%
3Y Avg
141.32%
5Y Avg
115.74%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$1.14M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Artelo Biosciences, Inc. (ARTL) | $1.36M | -253.57% | -227.69% | -154.33% | -104.05% |
| Genprex, Inc. (GNPX)vs › | $1.37M | -111.51% | -753.43% | -507.39% | -356.28% |
| INVO Fertility, Inc. (IVF)vs › | $1.48M | -32.05% | -197.10% | -44.98% | -69.38% |
| PMGC Holdings Inc. (ELAB)vs › | $1.49M | -80.57% | -96.07% | -115.92% | 51.19% |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.50M | -169.64% | 97.92% | 65.28% | 65.28% |
| Curis, Inc. (CRIS)vs › | $1.54M | -450.54% | 292.29% | 55.45% | 24.80% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.17M | N/A | 206.72% | 141.32% | 115.74% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.14M | -11.85% | -6.20% | 47.36% | 47.36% |
| Clearmind Medicine Inc. (CMND)vs › | $1.11M | -57.87% | -222.45% | -164.72% | -135.78% |
ROE
-253.6%
ROA
-196.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -253.57% |
| 2026-03-31 | -201.81% |
| 2024-12-31 | -343.93% |
| 2024-09-30 | -143.39% |
| 2024-06-30 | -143.01% |
| 2024-03-31 | -100.70% |
| 2023-12-31 | -79.04% |
| 2023-09-30 | -65.54% |
| 2023-06-30 | -58.00% |
| 2023-03-31 | -58.32% |
| 2022-12-31 | -51.97% |
| 2021-11-30 | -31.47% |
| 2021-08-31 | -61.76% |
| 2021-05-31 | -55.20% |
| 2021-02-28 | -41.07% |
| 2020-11-30 | -52.83% |
| 2020-08-31 | -120.13% |
| 2020-05-31 | -138.70% |
| 2020-02-29 | -104.29% |
| 2019-11-30 | -58.86% |
| 2019-08-31 | -39.77% |
| 2018-02-28 | -290.12% |
| 2017-11-30 | -170.89% |
| 2017-08-31 | -43.11% |
| 2015-11-30 | -186.13% |
| 2015-08-31 | -99.68% |
| 2015-05-31 | -88.82% |
| 2015-02-28 | -255.65% |
| 2014-11-30 | -117.23% |
| 2014-08-31 | -126.04% |
